Selank and Semax Research: Co-Investigation of Two Synthetic Regulatory Peptides in Preclinical Nootropic and Anxiolytic Models

Published by the Elite Biologix Research Team — Independent research compilation for scientific and educational reference only.

Key Takeaways

• Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and Semax (Met-Glu-His-Phe-Pro-Gly-Pro) are synthetic heptapeptides built on different endogenous fragments, tuftsin and ACTH(4-7) respectively, but both carry the same Pro-Gly-Pro stabilizing extension (Zozulya et al., Bull Exp Biol Med, 2001, PMID: 11550013; Dolotov et al., Bioorg Khim, 2004, PMID: 15344653).
• Selank's best-characterized biochemical mechanism is inhibition of enkephalin-degrading enzymes with an in vitro IC50 of 15 µM, exceeding bacitracin and puromycin (PMID: 11550013).
• Semax's best-characterized mechanism is BDNF-TrkB pathway induction, with a single 50 µg/kg intranasal dose raising rat hippocampal BDNF protein about 1.4-fold and TrkB phosphorylation about 1.6-fold (Dolotov et al., Brain Research, 2006, PMID: 16996037).
• Both compounds independently increase hippocampal BDNF in rodents, which is the primary reason investigators design co-administration protocols rather than treating them as unrelated tools (Inozemtseva et al., 2008, PMID: 18841804).
• As of 2026, neither peptide is approved for human use by the FDA or any major Western regulatory authority. All data cited below comes from in vitro assays and controlled rodent models.

Selank and Semax are frequently discussed together in the preclinical literature, and there is a concrete scientific reason for that pairing. Both emerged from the same research program at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are heptapeptides. Both were designed by attaching a Pro-Gly-Pro tripeptide to a short endogenous regulatory fragment in order to defeat rapid peptidase cleavage. And both have been studied predominantly by intranasal administration in rodents, which makes their experimental protocols unusually easy to run in parallel.

What they do not share is a receptor system. That divergence is the whole point of studying them together. This article reviews what the published preclinical record actually establishes about each compound, where the mechanisms separate, where the measured endpoints converge, and what methodological problems a researcher inherits when designing a combined-administration study in animal models.

Why Do Researchers Co-Investigate Selank and Semax in Preclinical Models?

The two peptides act on non-overlapping upstream targets while converging on a shared downstream marker. Selank inhibits enkephalin-degrading enzymes at an in vitro IC50 of 15 µM (Zozulya et al., Bull Exp Biol Med, 2001, PMID: 11550013), while Semax binds basal forebrain membrane sites with a Kd of 2.41 ± 1.02 nM (Dolotov et al., 2004, PMID: 15344653).

That combination is what pharmacologists call mechanistic orthogonality: two agents that reach a common readout through separate entry points. In rodent models, both compounds raise hippocampal BDNF, but Selank does so from a peptidase-inhibition and GABAergic-transcription starting point, while Semax does so through melanocortin-family receptor engagement and direct neurotrophin gene transcription. Researchers designing dissociation experiments find that structure useful, because a shared endpoint reached by two routes can be probed with selective blockade of one route at a time.

There is a second, more practical reason. Both peptides have published intranasal rodent protocols with characterized brain penetration. Semax intranasal pharmacokinetic work in rodents detected 0.093% of total radioactivity per gram of brain tissue at two minutes post-administration, with roughly 80% of that signal representing intact peptide (Shevchenko et al., Bioorg Khim, 2006, PMID: 16523722). Selank's BDNF work used the same intranasal route in rats (Inozemtseva et al., Doklady Biological Sciences, 2008, PMID: 18841804). Matched routes remove a major confound from any parallel-arm design.

What the shared Pro-Gly-Pro extension means for study design

Both molecules degrade to Pro-Gly-Pro, and that tripeptide is itself an endogenous CNS-active peptide. In the ischemia literature, Pro-Gly-Pro was run as a separate comparison arm against Semax and produced broader, less temporally selective neurotrophin induction (Dmitrieva et al., Cell Mol Neurobiol, 2010, PMID: 19633950). Any co-administration protocol therefore generates a third pharmacologically active species from two parent compounds, and the metabolite pool is shared rather than distinct.

How Do the Two Peptides Compare Structurally and Mechanistically?

Selank and Semax differ in parent fragment, receptor system, and the endpoints their literatures actually measure. Selank derives from tuftsin, an immunomodulatory IgG fragment; Semax derives from ACTH(4-7), a melanocortin fragment. The functional consequence shows in the data: Selank's record is densest in anxiety-related behavioral endpoints and cytokine work, Semax's in neurotrophin signaling and ischemia transcriptomics.

Research note: Co-administration designs pairing Selank and Semax are methodologically interesting for a reason that is easy to miss. Most combination pharmacology in the neuropeptide space pairs agents that share a receptor family, which makes additive effects trivially expected and mechanistically uninformative. Selank and Semax do not share one. One enters through peptidase inhibition of the endogenous enkephalin pool and a GABAergic transcriptional signature; the other enters through melanocortin-family membrane binding and direct neurotrophin gene induction. Yet both converge on hippocampal BDNF in rodents. That makes the pairing a genuine test case for whether two independent upstream routes to the same neurotrophin endpoint produce additive, occlusive, or supraadditive readouts. Occlusion would argue for a shared rate-limiting downstream step; additivity would argue for parallel pathways. Complicating both interpretations, the two compounds release the same Pro-Gly-Pro metabolite, so a combined arm raises that shared species more than either single arm does. Any co-administration protocol should therefore include a standalone Pro-Gly-Pro control arm, which most published single-agent work already provides a template for (PMID: 19633950).

Elite Biologix supplies Selank and Semax at ≥98% purity, verified by third-party batch testing with a published Certificate of Analysis, specifically for use in qualified research environments. View our Selank research compound · View our Semax research compound.

What Does the Selank Arm Contribute to a Co-Investigation?

Selank contributes anxiolytic-model behavior and an enkephalin-system entry point that Semax does not have. The 2001 characterization established dose-dependent inhibition of enkephalin-degrading enzymes in plasma preparations at IC50 15 µM, exceeding both bacitracin and puromycin (Zozulya et al., 2001, PMID: 11550013). A companion behavioral study confirmed the functional consequence.

In that companion work, Selank at 100 µg/kg extended plasma leu-enkephalin half-life and produced anxiolytic-model effects in the open field, but only in BALB/c mice. C57Bl/6 mice showed neither result (Sokolov et al., Bull Exp Biol Med, 2002, PMID: 12432865). Strain is therefore a primary experimental variable, not a housekeeping detail, and a co-administration study run in the wrong strain could report a null Selank arm for reasons unrelated to the combination.

GABAergic transcription and combination precedent

Intranasal Selank at 300 µg/kg altered expression of 45 of 84 assayed GABAergic neurotransmission genes in rat frontal cortex at one hour, with 22 still altered at three hours, and the one-hour pattern correlated positively with the effects of exogenous GABA itself (Volkova et al., Frontiers in Pharmacology, 2016, PMID: 26924987). Selank is not a direct GABA-A agonist, so this is a transcriptional resemblance rather than receptor mimicry.

The Selank literature also contains the field's clearest precedent for combined administration with a second agent. Under a 14-day unpredictable chronic mild stress protocol, Selank (300 µg/kg intranasal) combined with diazepam (1 mg/kg oral) produced an 8.9-fold increase in elevated plus-maze open-arm residence time versus saline-treated stressed controls, exceeding either compound alone (Kasian et al., Behavioural Neurology, 2017, PMID: 28280289). That study is the methodological template most co-investigation protocols borrow from. For the full preclinical record on Selank, see our Selank research review.

Selank's peripheral signature rounds out the picture. Under a 20-day social stress protocol at 100 µg/kg/day IP, Selank normalized elevated IL-1β, IL-6, and TGF-β1 and suppressed TNF-α toward unstressed control values in rats (Yasenyavskaya et al., Curr Rev Clin Exp Pharmacol, 2021, PMID: 32621722). A broader review of this peptide class places both compounds in the same design lineage of stabilized endogenous fragments (Kolomin et al., Regulatory Peptides, 2011, PMID: 21609736).

What Does the Semax Arm Contribute?

Semax contributes the deeper neurotrophin and neuroprotection dataset. A single 50 µg/kg intranasal dose raised rat hippocampal BDNF protein about 1.4-fold, exon III BDNF mRNA about 3-fold, TrkB mRNA about 2-fold, and TrkB tyrosine phosphorylation about 1.6-fold (Dolotov et al., Brain Research, 2006, PMID: 16996037). Receptor-level activation data of that kind has no Selank equivalent.

The induction is anatomically selective. BDNF protein rose in basal forebrain but not cerebellum, matching the regional distribution of melanocortin receptor expression in rodent brain (Dolotov et al., J Neurochem, 2006, PMID: 16635254). Later work found the induction pattern to be time-dependent and multidirectional across hippocampus, frontal cortex, and retina rather than a uniform bulk response (Glazova et al., J Mol Neurosci, 2009, PMID: 19662538). Sampling timepoint matters as much as region.

Ischemia and stress-model endpoints

In a transient MCAO rat model, transcriptome analysis identified 394 Semax-responsive genes at 24 hours in subcortical tissue, of which 312 moved directly against the ischemia-reperfusion expression pattern (Filippenkov et al., Genes (Basel), 2020, PMID: 32580520). Protein-level work in the same model reported increased active CREB alongside decreased MMP-9, c-Fos, and active JNK (Sudarkina et al., Int J Mol Sci, 2021, PMID: 34201112).

Semax also carries stress-model data that overlaps conceptually with Selank's. At 60 nmol/kg/day IP in a chronic unpredictable stress rat paradigm, researchers observed reversal of stress-induced anhedonia by sucrose preference test, attenuated adrenal hypertrophy, and restoration of suppressed hippocampal BDNF (Inozemtseva et al., Eur J Pharmacol, 2024, PMID: 39442746). Separately, striatal microdialysis showed Semax at 0.15 mg/kg IP raising extracellular 5-HIAA to roughly 180% of baseline over one to four hours without directly elevating dopamine (Inozemtseva et al., Neurochemical Research, 2006, PMID: 16362768). For the full preclinical record on Semax, see our Semax research review.

Where Do the Two Literatures Actually Converge?

They converge at hippocampal BDNF and at stress-paradigm behavior, and nowhere else with comparable rigor. A single intranasal Selank dose raised rat hippocampal BDNF mRNA at 3 hours and BDNF protein at 24 hours (Inozemtseva et al., 2008, PMID: 18841804), a temporal sequence broadly parallel to Semax's, though measured with far less receptor-level depth.

The evidence depth is genuinely asymmetric, and researchers should plan around it. Semax's BDNF claim rests on multiple studies including TrkB phosphorylation quantification and region-by-region dissociation. Selank's rests substantially on the single 2008 study plus a pathological-context extension showing that 0.3 mg/kg IP over 7 days prevented ethanol-induced BDNF elevation in hippocampus and frontal cortex while protecting object recognition performance during withdrawal (Kolik et al., Bull Exp Biol Med, 2019, PMID: 31625062).

Cognitive-endpoint overlap is thinner still. Selank improved conditioned active avoidance performance in rats with poor baseline learning, reducing errors and increasing correct responses (Kozlovskii and Danchev, Neurosci Behav Physiol, 2003, PMID: 14552529), while Semax's learning-related data sits mostly inside hypoxia-ischemia and neurotrophin contexts. The two are measuring different constructs in different paradigms, so a co-administration study has to pre-specify which construct it is actually testing.

What Methodological Cautions Apply to Combined-Administration Research?

Four constraints dominate. First, strain selection: Selank's behavioral effects were present in BALB/c and absent in C57Bl/6 in the same experiment (PMID: 12432865), so a combined arm run in C57Bl/6 risks a false null attributable to strain rather than to pharmacology.

Second, timepoint mismatch. Selank's GABAergic transcriptional signature is largest at one hour and substantially decayed by three (PMID: 26924987), while its BDNF protein signal peaks near 24 hours (PMID: 18841804). Semax's hippocampal markers cluster around 3 hours (PMID: 16996037) but its ischemia transcriptome is read at 24 (PMID: 32580520). No single sampling window captures both compounds at peak.

Third, the shared metabolite problem described earlier. Fourth, geographic concentration of the source literature: nearly all of this work originates from a small cluster of Moscow-area institutions, with limited independent Western replication. That is a real limitation on both compounds and it applies with equal force to any conclusion drawn about the pair.

We've found that the most defensible co-investigation designs treat the combination as a four-arm question rather than a two-arm one: vehicle, Selank alone, Semax alone, and both together, with a Pro-Gly-Pro reference arm where budget allows. Anything less cannot distinguish additivity from metabolite accumulation.

Frequently Asked Questions About Selank and Semax Preclinical Research

Are Selank and Semax structurally related?

They share an architecture, not a sequence. Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, built on the tuftsin tetrapeptide; Semax is Met-Glu-His-Phe-Pro-Gly-Pro, built on ACTH(4-7). Both were designed by appending a Pro-Gly-Pro tripeptide to a short endogenous fragment to block peptidase cleavage and extend biological half-life in preclinical systems (PMID: 11550013; PMID: 15344653).

Has combined administration of Selank and Semax been directly studied in animal models?

The published record does not contain a head-to-head combined-administration study of these two peptides indexed on PubMed. The nearest methodological precedent is the Selank plus diazepam combination under unpredictable chronic mild stress, which reported an 8.9-fold increase in elevated plus-maze open-arm time versus stressed controls (PMID: 28280289). Researchers should treat co-investigation as an open experimental question, not a documented finding.

Why do researchers describe the two mechanisms as complementary?

Because the upstream targets differ while a downstream marker overlaps. Selank's characterized action is enkephalin-degrading enzyme inhibition at IC50 15 µM in vitro plus GABAergic gene expression shifts (PMID: 11550013; PMID: 26924987). Semax's is melanocortin-family membrane binding at Kd 2.41 nM plus BDNF-TrkB induction (PMID: 15344653; PMID: 16996037). Both raise hippocampal BDNF in rodents through separate routes.

Which compound has the deeper published evidence base?

It depends on the endpoint. Semax has substantially deeper neurotrophin and ischemia data, including receptor phosphorylation quantification and a 394-gene transcriptome response in transient MCAO rats (PMID: 16996037; PMID: 32580520). Selank has deeper anxiolytic-model behavioral data, the only enkephalinase IC50 characterization of the pair, and more developed cytokine work under social stress protocols (PMID: 32621722).

Are Selank or Semax approved for human use?

Neither is approved for human use by the FDA or any major Western regulatory authority. Limited registrations exist in Russia, which do not constitute international approval. Every finding cited in this article comes from in vitro biochemical assays or controlled rodent model studies, and rodent results cannot be presumed to translate to human physiology. Both compounds are sold exclusively for laboratory and research purposes.

Conclusion: What the Co-Investigation Literature Supports

The scientific case for studying Selank and Semax together is structural, not anecdotal. They are sibling molecules from one design program, they share a stabilizing extension and a metabolite, they use compatible intranasal rodent protocols, and they reach a common neurotrophin endpoint from genuinely different upstream positions. Those properties make the pairing a clean test bed for parallel-pathway questions that same-family combinations cannot answer.

What the literature does not yet support is any claim about the combination itself. No direct co-administration study of the two peptides appears in the indexed record. The evidence depth is asymmetric, the source institutions are geographically concentrated, and the peak-signal timepoints do not align. Researchers designing in this space should build those four constraints into the protocol at the outset rather than discovering them in the analysis. Our standalone reviews of Selank and Semax cover each compound's full preclinical record in depth.

For qualified research environments, Elite Biologix supplies both compounds at ≥98% purity, each verified by third-party batch testing with a published Certificate of Analysis covering identity, purity, quantitative assay, heavy metals by ICP-MS, and microbial counts (TAMC/TYMC). View our Selank research compound · View our Semax research compound.

References

1. Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LA, Myasoedov NF, Nesmeyanov VA. Inhibition of Enkephalin-Degrading Enzymes by Selank. Bulletin of Experimental Biology and Medicine. 2001. PMID: 11550013.
2. Sokolov OYu, Meshavkin VK, Kost NV, Zozulya AA. Effects of Selank on Behavioral Reactions and Activity of Enkephalin-Degrading Enzymes in BALB/c and C57Bl/6 Mice. Bulletin of Experimental Biology and Medicine. 2002. PMID: 12432865.
3. Kozlovskii II, Danchev ND. The Optimizing Action of the Synthetic Peptide Selank on a Conditioned Active Avoidance Reflex in Rats. Neuroscience and Behavioral Physiology. 2003. PMID: 14552529.
4. Dolotov OV, Karpenko EA, Seredenin SB, Andreeva LA, Grivennikov IA, Myasoedov NF. Semax, an Analogue of ACTH(4-7) with Prolonged Action, Binds Specifically and Modulates BDNF in the Rat Basal Forebrain. Bioorganicheskaya Khimiya. 2004. PMID: 15344653.
5. Inozemtseva LS, Dolotov OV, Grivennikov IA, Myasoedov NF. Intranasal Administration of Semax and Its Metabolite Pro-Gly-Pro Affects Rat Brain Monoaminergic Systems. Neurochemical Research. 2006. PMID: 16362768.
6. Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Pharmacokinetics of Intranasal Semax. Bioorganicheskaya Khimiya. 2006. PMID: 16523722.
7. Dolotov OV, Inozemtseva LS, Seredenin SB, Grivennikov IA, Myasoedov NF. Semax, an Analogue of ACTH(4-10), Binds Specifically and Increases Levels of BDNF Protein in Rat Basal Forebrain. Journal of Neurochemistry. 2006. PMID: 16635254.
8. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenin SB, Kasian AO, Grivennikov IA, Myasoedov NF. Semax and Its C-Terminal Tripeptide Activate BDNF in the Rat Hippocampus. Brain Research. 2006. PMID: 16996037.
9. Inozemtseva LS, Dolotov OV, Grivennikov IA. Intranasal Administration of Selank Elevates BDNF mRNA and Protein in Rat Hippocampus. Doklady Biological Sciences. 2008. PMID: 18841804.
10. Glazova MV, Manchenko DM, Volodina MA, Rybalkina EY, Dolotov OV, Grivennikov IA. Semax Stimulates BDNF Production and Prevents Learning and Memory Deficiencies in Neonatal Rats with Hypoxia-Ischemia. Journal of Molecular Neuroscience. 2009. PMID: 19662538.
11. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Focal Brain Ischemia in Rats. Cellular and Molecular Neurobiology. 2010. PMID: 19633950.
12. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides. Regulatory Peptides. 2011. PMID: 21609736.
13. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016. PMID: 26924987.
14. Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017. PMID: 28280289.
15. Kolik LG, Nadorova AV, Pravdivtseva OE. Effect of Selank on Behavioral Changes Caused by Ethanol and Dynamics of BDNF in Brain Structures of Rats. Bulletin of Experimental Biology and Medicine. 2019. PMID: 31625062.
16. Filippenkov IB, Remizova JA, Denisova AE, Stavchansky VV, Golubeva AE, Limborska SA, Myasoedov NF, Dergunova LV. Semax (ACTH(4-7)-Pro-Gly-Pro) Affects the Transcriptomic Changes Caused by Transient Focal Brain Ischemia in Rats. Genes (Basel). 2020. PMID: 32580520.
17. Yasenyavskaya AL, Shakhbazov AV, Linkova NS, Kvetnoy IM, Samotrueva MA. Influence of Selank on the Level of Pro- and Anti-Inflammatory Cytokines in Conditions of Social Stress in Rats. Current Reviews in Clinical and Experimental Pharmacology. 2021. PMID: 32621722.
18. Sudarkina OY, Filippenkov IB, Stavchansky VV, Denisova AE, Yuzhakov VV, Sevan'kaeva LE, Valieva LV, Limborska SA, Myasoedov NF, Dergunova LV. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences. 2021. PMID: 34201112.
19. Inozemtseva LS, Dolotov OV, Levitskaya NG, Grivennikov IA, Myasoedov NF. Semax Produces Antidepressant-Like Effects in the Chronic Unpredictable Stress Model in Rats. European Journal of Pharmacology. 2024. PMID: 39442746.

Selank and Semax are sold exclusively for laboratory and research purposes. They are not approved for human use by the FDA or any regulatory authority. All information presented in this article is derived from published preclinical research using in vitro assays and animal models. Findings from rodent studies cannot be presumed to translate directly to human physiology. Elite Biologix does not make any claims regarding the safety or efficacy of Selank or Semax for use in humans or animals.